Targeted pill plus chemo before surgery for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two different treatment plans before lung cancer surgery. Both plans start with a targeted pill (limertinib), then one adds immunotherapy plus chemotherapy, and the other adds just chemotherapy. The goal is to see which combination helps shrink the tumor more before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called adenocarcinoma that can be removed with surgery.
- Your lung cancer is stage II, IIIA, or IIIB (has not spread far).
- You have not yet had any treatment for this cancer.
- You have an EGFR gene change in your cancer (found by a lab test on a biopsy or blood sample).
- You are between 18 and 75 years old and are well enough for daily activities (ECOG 0 or 1).
- Your heart, liver, kidneys, and blood counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if taking a targeted therapy drug before surgery can help shrink tumors in people with a specific type of lung cancer called EGFR-mutated squamous cell carcinoma that can be removed with surgery. The goal is to see if this approach improves outcomes.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial tests giving chemotherapy followed by the immunotherapy drug sintilimab before surgery for people with EGFR-mutant, early-stage non-small cell lung cancer. It aims to see if this combination reduces the tumor and improves outcomes before surgical removal.
This study tests whether combining an EGFR-targeted pill with chemotherapy before surgery can shrink or control early-stage non-small cell lung cancer that has an EGFR mutation. It aims to improve outcomes for patients whose tumors can be removed surgically.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.